Shares of Wockhardt Ltd. surged 18.80% to a near two-year high on Monday, as it successfully completed phase-3 pneumonia study of macrolide antibiotic Nafithromycin.
The study result showed that a short course of three-day treatment with Nafithromycin is as effective as seven-day therapy with Moxifloxacin.
Nafithromycin or Wockhardt NCE, WCK 4873 was comparatively evaluated in a multi-centre double blind phase-3 pneumonia study, employing the last-line respiratory antibiotic Moxifloxacin, an exchange filing said.
Shares of the company rose 18.8%, the most since Jan. 17, 2022, before paring gains to trade 15.48% higher at 12:42 p.m. This compares to a 0.02% advance in the NSE Nifty 50.
The stock has risen 74.67% year-to-date. Total traded volume so far in the day stood at 3.6 times its 30-day average. The relative strength index was at 76.22.
RECOMMENDED FOR YOU
Garden Reach Shipbuilders' Share Price Gains After Q2 Profit, Revenue Jump
Nov 14, 2024
NHPC Share Price Falls Nearly 5% As Profit Declines More Than Estimates
Nov 08, 2024
Wockhardt Seeks To Raise Rs 1,000 Crore Via Share Sale To Institutions
Nov 07, 2024
Wockhardt Share Price At Over Eight-Year High After Filing Insulin Injection With Regulator
Oct 16, 2024
POPULAR